Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of Extraordinary General Meeting scheduled to be held on Saturday, January 31, 2026
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has called an Extra-Ordinary General Meeting (EGM) on Saturday, January 31, 2026, at 12:30 PM via video conferencing. The sole business is to seek shareholder approval (via special resolution) for issuing up to 11,70,000 fully convertible equity warrants on a preferential/private placement basis to members of the Promoter and Promoter Group. The warrants carry an exercise/conversion price of ₹812 per share (face value ₹10 + premium of ₹802), aggregating to roughly ₹95 crore in total consideration. Allottees include Swapnil Jatin Shah (1.97 lakh warrants), Ashokbhai Vijaysinh Barot (1.23 lakh), Renosen Pharmaceuticals Pvt Ltd (7.39 lakh), Sangeeta Mukur Barot (61,500), and Viraj Ashokkumar Barot (49,500). Allottees must pay 25% upfront (₹203 per warrant) and the balance upon conversion within 18 months, and the issue is intended to fund the company's working capital requirements.
Existing shareholders may see modest dilution if all warrants are converted into equity shares, but since the preferential issue is going to the promoter group (not new external investors), control of the company will not change. The ₹95 crore inflow will strengthen the company's working capital, which is a neutral-to-mildly-positive operational signal, though it also signals the promoters are committing additional capital to back the business.